FOUNDAYO / ORFORGLIPRON — CURRENT UK HUB
Foundayo in the UK: the daily GLP-1 pill without a fasting window
Foundayo is the brand name for orforglipron, an MHRA-authorised prescription GLP-1 tablet. It offers a different daily routine from the Wegovy pill, but convenience is only one part of a responsible treatment decision.
Written and researched by Matt O’Brien, founder of Shift Some Timber. Evidence reviewed 2026-08-26.
Starting Foundayo: the practical questions
What did the main weight-management trial find?
ATTAIN-1 randomly assigned 3,127 adults with overweight or obesity, without type 2 diabetes, to orforglipron or placebo for 72 weeks. Everyone received diet and activity counselling. In the intention-to-treat results reported in the UK product information, average weight loss was 12.4% in the highest-dose trial group and 0.9% with placebo.
This is a group average, not a prediction for you or a direct comparison with Wegovy or Mounjaro. Trial dose figures should not be used to choose your prescribed tablet strength. Nausea, vomiting and diarrhoea can occur; gastrointestinal effects can sometimes be severe and cause dehydration. Read the urgent warning signs in the linked first-month plan and discuss suitability and tolerability with your prescriber.
Source: UK Foundayo product information, sections 4.4 and 5.1, updated 14 August 2026; checked 6 October 2026.
Foundayo has its own instructions. Do not borrow Wegovy’s fasting rules or missed-dose advice. The UK leaflet permits a daily dose at any time, with or without food. Ask the pharmacist to check your other medicines and supplements; the absence of a fasting window does not mean there are no interactions.
Choose a daily anchor you can repeat. Before each new prescription, confirm the strength, review plan and total cost with your service. Do not change the dose yourself.
For a missed dose, follow the Foundayo leaflet: take it when remembered, with no more than one dose in a day and no double dose. If several days were missed or you vomit after taking it, ask the pharmacist before guessing a restart or replacement.
Use the shared first-month plan for food, practical check-ins and urgent warning signs, and compare the daily routines and costs.
Open My Timber’s Today screen and look for “Your tablet routine”. If these tablets have already been prescribed for you, optional health tracking lets you save a routine, return for a first-week check-in and say whether a practical step helped. You can use routine support when treatment was arranged elsewhere. Saving a check-in does not contact a clinician; nobody monitors it for symptoms. Medicine decisions stay with your prescribing service.
For everyday support, use food and meal planning and manageable movement and starting steps.
Sources: MHRA: Wegovy tablets authorised, 11 June 2026; MHRA: Foundayo authorised, 10 August 2026; UK Wegovy tablet leaflet, revised June 2026; UK Foundayo leaflet, revised August 2026.
Practical section added and its linked sources checked 6 October 2026 by the SHIFT editorial team. These are general examples, not a personal diet, exercise or treatment prescription. Independent clinical review is not claimed.
What changed in August 2026
On 10 August 2026 the MHRA authorised orforglipron, branded Foundayo, for weight management and type 2 diabetes in defined adult populations. The UK became the first country in Europe to authorise it.
That means older pages describing Foundayo as merely experimental or not UK-authorised are now stale. It does not mean automatic NHS access, universal suitability or that every advertised online product is legitimate.
How Foundayo differs from the Wegovy pill
Both are daily GLP-1 tablets, but they contain different active ingredients. Wegovy tablets contain semaglutide and require an overnight fast, a small amount of water and a wait before food or drink. Foundayo contains orforglipron and has a more flexible relationship with food and water.
The easier routine may matter to people who take other morning medicines, work shifts or struggle with fasting instructions. It does not make Foundayo clinically better for every individual.
Doses, evidence and expectations
Foundayo uses a staged dose-escalation route. The exact current strengths and product instructions must be checked against the authorised UK product information rather than copied from an older trial or another country's label.
Trial averages can describe what happened across a study population. They cannot predict an individual's result, and separate Foundayo, Wegovy and Mounjaro trials are not direct head-to-head comparisons.
Side effects and assessment
Get urgent medical help for severe stomach pain that does not go away, especially if it spreads to your back, with or without vomiting. This can indicate pancreatitis. Do not wait for a routine review or company reply. A clinician must assess it; if pancreatitis is confirmed, the medicine must not be restarted.
Read the instructions for your exact product and discuss side effects with your prescriber or pharmacist: Foundayo UK product information. Safety information checked 3 October 2026.
Gastrointestinal effects such as nausea, vomiting, diarrhoea and constipation can occur with GLP-1 medicines. Suitability depends on medical history, current medicines, risks and the prescriber's assessment.
Use a regulated prescribing and pharmacy service. Do not buy products presented as weight-loss medicines through social media, gyms or unregulated sellers.
Price, private availability and NHS access
Private launch prices and provider availability can move rapidly. Any Shift price tracker must display the provider, strength, date checked and what the price includes.
NHS use requires separate assessment through NICE and implementation decisions. 'MHRA-authorised', 'available privately' and 'available through the NHS' must never be treated as interchangeable statements.
Frequently asked questions
What is Foundayo?
Foundayo is the brand name for orforglipron, a prescription-only daily GLP-1 tablet authorised by the MHRA in August 2026 for defined adult populations.
Is Foundayo the same as the Wegovy pill?
No. Foundayo contains orforglipron while Wegovy tablets contain semaglutide. They have different molecules, product instructions and evidence records.
Does Foundayo require the Wegovy fasting routine?
No. Foundayo has a more flexible relationship with food and water, although users must follow the current product information and their prescriber's instructions.
Useful next steps
Sources you can inspect
- MHRA — UK authorisation of orforglipron (Foundayo)
- NICE — overweight and obesity management
- NHS — obesity
Sources support general information, not an individual suitability decision. External organisations remain responsible for their own content.
Who wrote this?
Matt O’Brien owns the research, writing and plain-English interpretation. Matt lost around 4½ stone over about eleven months through changes to eating, movement and prescribed weight-loss treatment after a clinical assessment. This is his personal experience, not a promise of results. He is not a clinician or prescriber. Read Matt’s full story.